Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors

Science

Volumn 313, Issue 5794, 2006, Pages 1785-1787

  Shaked, Yuval ^a   Ciarrocchi, Alessia ^b   Franco, Marcela ^a   Lee, Christina R ^a   Man, Shan ^a   Cheung, Alison M ^a   Hicklin, Daniel J ^c   Chaplin, David ^d   Foster, F Stuart ^a   Benezra, Robert ^b   Kerbel, Robert S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d OXiGENE Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSELS; CELLS; DRUG THERAPY; GENES; TUMORS;

ANTIANGIOGENIC DRUGS; CIRCULATING ENDOTHELIAL PROGENITOR CELLS (CEP); VASCULAR DISRUPTING AGENTS (VDA);

BIOMEDICAL ENGINEERING;

VASCULAR TARGETING AGENT;

CELLS AND CELL COMPONENTS; TUMOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; GENETIC MANIPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CELL HYPOXIA; CELL LINE, TUMOR; DIPHOSPHATES; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; NECROSIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS; STILBENES;

EID: 33749005405     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1127592     Document Type: Article

References (20)

1. T. Asahara et al., Science 275, 964 (1997).
2. S. Rafii, D. Lyden, R. Benezra, K. Hattori, B. Heissig, Nat. Rev. Cancer 2, 826 (2002).
3. M. Heil, T. Ziegelhoeffer, B. Mees, W. Schaper, Circ. Res. 94, 573 (2004).
4. B. A. Peters et al., Nat. Med. 11, 261 (2005).
5. D. W. Siemann, D. J. Chaplin, M. R. Horsman, Cancer 100, 2491 (2004).
6. G. M. Tozer, C. Kanthou, B. C. Baguley, Nat. Rev. Cancer 5, 423 (2005).
7. Y. Shaked et al., Cancer Cell 7, 101 (2005).
8. M. Prewett et al., Cancer Res. 59, 5209 (1999).
9. D. W. Siemann, A. M. Rojiani, Int. J. Radiat. Oncol. Biol. Phys. 62, 846 (2005).
10. F. S. Foster, Ultrasound Med. Biol. 28, 1165 (2002).
11. M. Franco et al., Cancer Res. 66, 3639 (2006).
12. M. De Palma et al., Cancer Cell 8, 211 (2005).
13. M. Grunewald et al., Cell 124, 175 (2006).
14. D. Lyden et al., Nat. Med. 7, 1194 (2001).
15. M. B. Ruzinova et al., Cancer Cell 4, 277 (2003).
16. D. Lyden et al., Nature 401, 670 (1999).
17. F. Bertolini et al., Cancer Res. 63, 4342 (2003).
18. C. Urbich, S. Dimmeler, Circ. Res. 95, 343 (2004).
19. Y. Shaked et al., Cancer Res. 65, 7045 (2005).
20. We thank C. Cheng for excellent secretarial and editorial assistance and P. Stefanova for technical support. Supported by grants from the Canadian Institutes of Health Research (CIHR) and the National Cancer Institute of Canada (NCIC), NIH grant CA-41233 (R.S.K.), NIH grant ROl CA-107429 (R.B.), a CIHR fellowship award (Y.S.), an American-Italian Cancer Foundation fellowship award (A.C.), and sponsored research agreements with ImClone Systems Inc. (R.S.K.) and VisualSonic (F.S.F.). All animal work was carried out according to the institutional guidelines at Sunnybrook Health Sciences Centre and Memorial Sloan-Kettering Cancer Center. R.S.K. has a paid consulting relationship with OXiGENE, ImClone Systems Inc., and VisualSonic.